Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsfiledCriticalBayer Pharma AG
Publication of AR099464A1publicationCriticalpatent/AR099464A1/es
C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
ARP150100401A2014-02-112015-02-11Benzimidazol-2-aminas como inhibidores de midh1
AR099464A1
(es)